SeaStar Medical to Hold Business Update Conference Call Today at 4:00 p.m. Eastern Time

DENVER, Aug. 22, 2023 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will hold a business update conference call today at 4:00 p.m. Eastern time (1:00 p.m. Pacific time). During the call, management will provide a clinical and regulatory update and review the Company’s value proposition, including the commercial opportunity.

A slide presentation to accompany management’s prepared remarks will be available on the webcast and on the Events and Presentations page of the Investors section of the SeaStar Medical website at seastarmedical.com.

Date: Today, Tuesday, August 22, 2023
Time: 4:00 p.m. Eastern time (1:00 p.m. Pacific time)

Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

Stockholders and other interested parties may also participate in the conference call by dialing 866-777-2509 from within the U.S. or 412-317-5413 from outside the U.S., and requesting the SeaStar Medical call.

A live webcast of the call will be available here and will be archived for 90 days. A replay of the call will be available beginning two hours after the call ends through August 24, 2023 by dialing 877-344-7529 from within the U.S., 855-669-9658 from Canada or 412-317-0088 from outside the U.S. and Canada, and entering the conference identification number 8122409.

About SeaStar Medical

SeaStar Medical is a medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or Twitter.

Contact:
LHA Investor Relations
Jody Cain
(310) 691-7100
Jcain@lhai.com

# # #